Total Payments
$467,945
2024 Payments
$6,450
Companies
75
Transactions
1,882
Medicare Patients
3,002
Medicare Billing
$339,502
Payment Breakdown by Category
Other$378,219 (80.8%)
Food & Beverage$40,214 (8.6%)
Consulting$28,850 (6.2%)
Travel$20,093 (4.3%)
Education$569.22 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $378,131 | 231 | 80.8% |
| Food and Beverage | $40,214 | 1,473 | 8.6% |
| Consulting Fee | $28,850 | 10 | 6.2% |
| Travel and Lodging | $20,093 | 137 | 4.3% |
| Education | $569.22 | 29 | 0.1% |
| Grant | $87.90 | 2 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ACADIA Pharmaceuticals Inc | $177,491 | 162 | $0 (2023) |
| Amgen Inc. | $68,621 | 149 | $0 (2024) |
| Lilly USA, LLC | $51,871 | 154 | $0 (2024) |
| ABBVIE INC. | $43,930 | 170 | $0 (2024) |
| Eisai Inc. | $43,676 | 112 | $0 (2024) |
| Acorda Therapeutics, Inc | $16,249 | 59 | $0 (2023) |
| Teva Pharmaceuticals USA, Inc. | $13,682 | 107 | $0 (2024) |
| Allergan, Inc. | $12,828 | 108 | $0 (2022) |
| Biohaven Pharmaceuticals, Inc. | $6,916 | 23 | $0 (2021) |
| Genentech USA, Inc. | $4,698 | 16 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $6,450 | 124 | ABBVIE INC. ($3,703) |
| 2023 | $16,054 | 154 | AbbVie Inc. ($7,495) |
| 2022 | $43,638 | 254 | Lilly USA, LLC ($17,858) |
| 2021 | $42,515 | 249 | AbbVie Inc. ($18,343) |
| 2020 | $68,014 | 272 | ACADIA Pharmaceuticals Inc ($16,569) |
| 2019 | $95,200 | 312 | ACADIA Pharmaceuticals Inc ($26,003) |
| 2018 | $99,519 | 244 | ACADIA Pharmaceuticals Inc ($55,860) |
| 2017 | $96,555 | 273 | ACADIA Pharmaceuticals Inc ($70,105) |
All Payment Transactions
1,882 individual payment records from CMS Open Payments — Page 1 of 76
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | PFIZER INC. | ZAVZPRET (Drug) | Food and Beverage | In-kind items and services | $16.24 | General |
| Category: PAIN | ||||||
| 12/17/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $18.92 | General |
| Category: PAIN | ||||||
| 12/12/2024 | Teva Pharmaceuticals USA, Inc. | AJOVY (Biological) | Food and Beverage | In-kind items and services | $20.54 | General |
| Category: Central Nervous System | ||||||
| 12/11/2024 | PFIZER INC. | ZAVZPRET (Drug) | Food and Beverage | In-kind items and services | $4.18 | General |
| Category: PAIN | ||||||
| 12/05/2024 | Lundbeck LLC | VYEPTI (Biological) | Food and Beverage | Cash or cash equivalent | $91.11 | General |
| Category: NEUROLOGY | ||||||
| 12/05/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $40.95 | General |
| 12/04/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $3.88 | General |
| Category: NEUROSCIENCE | ||||||
| 12/03/2024 | Neurelis, Inc. | VALTOCO (Drug) | Food and Beverage | In-kind items and services | $22.37 | General |
| Category: EPILEPSY | ||||||
| 11/22/2024 | InSightec,Inc | Exablate (Device) | Food and Beverage | Cash or cash equivalent | $20.20 | General |
| Category: Neurology | ||||||
| 11/19/2024 | Amneal Pharmaceuticals LLC | ONGENTYS (Drug) | Food and Beverage | In-kind items and services | $17.82 | General |
| Category: NEUROLOGY | ||||||
| 11/19/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $5.85 | General |
| Category: PAIN | ||||||
| 11/14/2024 | Life Molecular Imaging Ltd | NEURACEQ (Drug) | Food and Beverage | Cash or cash equivalent | $11.28 | General |
| Category: Diagnostic Tracer | ||||||
| 11/14/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $5.16 | General |
| Category: NEUROSCIENCE | ||||||
| 11/08/2024 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $22.48 | General |
| Category: NEUROSCIENCE | ||||||
| 11/07/2024 | UCB, Inc. | Nayzilam (Drug) | Food and Beverage | In-kind items and services | $104.23 | General |
| Category: Neurology | ||||||
| 11/07/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $9.18 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 11/07/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $6.01 | General |
| 10/29/2024 | Amneal Pharmaceuticals LLC | ONGENTYS (Drug) | Food and Beverage | In-kind items and services | $29.03 | General |
| Category: NEUROLOGY | ||||||
| 10/29/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $21.85 | General |
| Category: Neuropsychiatry | ||||||
| 10/22/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $26.18 | General |
| Category: NEUROSCIENCE | ||||||
| 10/10/2024 | JAZZ PHARMACEUTICALS INC. | EPIDIOLEX (Drug) | Food and Beverage | In-kind items and services | $20.85 | General |
| Category: NEUROLOGY | ||||||
| 10/09/2024 | Amneal Pharmaceuticals LLC | ONGENTYS 50MG CAPSULES 30 (Drug) | Food and Beverage | In-kind items and services | $27.23 | General |
| Category: NEUROLOGY | ||||||
| 10/09/2024 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $16.35 | General |
| Category: NEUROSCIENCE | ||||||
| 10/09/2024 | UCB, Inc. | Nayzilam (Drug) | Food and Beverage | In-kind items and services | $13.51 | General |
| Category: Neurology | ||||||
| 10/04/2024 | MDD US Operations, LLC | Gocovri (Drug) | Food and Beverage | In-kind items and services | $16.27 | General |
| Category: AMANTADINE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 598 | 728 | $226,485 | $69,396 |
| 2022 | 10 | 701 | 834 | $242,910 | $84,517 |
| 2021 | 11 | 782 | 912 | $231,915 | $89,639 |
| 2020 | 13 | 921 | 1,069 | $264,460 | $95,951 |
Total Patients
3,002
Total Services
3,543
Medicare Billing
$339,502
Procedure Codes
42
All Medicare Procedures & Services
42 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 202 | 260 | $71,500 | $21,538 | 30.1% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 146 | 159 | $55,650 | $20,388 | 36.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 73 | 76 | $31,800 | $9,367 | 29.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 58 | 58 | $29,000 | $8,731 | 30.1% |
| 64615 | Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | Office | 2023 | 12 | 35 | $17,500 | $3,792 | 21.7% |
| 95816 | Measurement of brain wave activity (eeg), awake and drowsy | Facility | 2023 | 69 | 76 | $11,400 | $3,209 | 28.1% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 12 | 36 | $3,960 | $1,399 | 35.3% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2023 | 26 | 28 | $5,675 | $972.43 | 17.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 213 | 278 | $76,450 | $24,765 | 32.4% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 151 | 158 | $55,300 | $23,626 | 42.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 92 | 92 | $38,950 | $14,202 | 36.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 53 | 57 | $23,900 | $7,326 | 30.7% |
| 95816 | Measurement of brain wave activity (eeg), awake and drowsy | Facility | 2022 | 84 | 93 | $10,870 | $4,081 | 37.5% |
| 64615 | Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | Office | 2022 | 12 | 32 | $16,000 | $3,923 | 24.5% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2022 | 35 | 38 | $7,600 | $2,121 | 27.9% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 16 | 21 | $3,150 | $1,580 | 50.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 33 | 33 | $7,170 | $1,526 | 21.3% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 12 | 32 | $3,520 | $1,367 | 38.8% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 189 | 203 | $71,050 | $30,506 | 42.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 147 | 180 | $49,500 | $17,001 | 34.3% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 72 | 72 | $25,200 | $11,262 | 44.7% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2021 | 105 | 125 | $25,225 | $6,594 | 26.1% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 82 | 85 | $14,875 | $5,444 | 36.6% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 35 | 36 | $10,800 | $5,181 | 48.0% |
| 95816 | Measurement and recording of brain wave (eeg) activity, awake and drowsy | Facility | 2021 | 100 | 113 | $9,605 | $5,098 | 53.1% |
About Dr. Peter Bellafiore, MD
Dr. Peter Bellafiore, MD is a Neurology healthcare provider based in Wakefield, Rhode Island. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/06/2006. The National Provider Identifier (NPI) number assigned to this provider is 1881753135.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Peter Bellafiore, MD has received a total of $467,945 in payments from pharmaceutical and medical device companies, with $6,450 received in 2024. These payments were reported across 1,882 transactions from 75 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($378,131).
As a Medicare-enrolled provider, Bellafiore has provided services to 3,002 Medicare beneficiaries, totaling 3,543 services with total Medicare billing of $339,502. Data is available for 4 years (2020–2023), covering 42 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Wakefield, RI
- Active Since 12/06/2006
- Last Updated 06/15/2020
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1881753135
Products in Payments
- NUPLAZID (Drug) $177,491
- Aimovig (Biological) $51,219
- UBRELVY (Drug) $44,987
- Fycompa (Drug) $43,427
- EMGALITY (Drug) $24,265
- INBRIJA (Drug) $15,857
- QULIPTA (Drug) $10,835
- NURTEC ODT (Drug) $9,230
- AJOVY (Drug) $7,620
- REYVOW (Drug) $7,343
- OCREVUS (Biological) $4,610
- KYNMOBI (Drug) $2,271
- TREXIMET (Drug) $2,204
- ONZETRA Xsail (Drug) $1,661
- ACTHAR (Biological) $1,407
- VYEPTI (Biological) $851.58
- Mavenclad (Drug) $837.05
- NUEDEXTA (Drug) $730.13
- RYTARY (Drug) $722.52
- APTIOM (Drug) $702.78
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.